Pfizer: Q4 EPS below estimates
(CercleFinance.com) - Pfizer has reported Q4 2019 adjusted EPS that is down 13% at 55 cents, two cents below the consensus, for revenue that is down 9% at 12.
7 billion dollars (-8% in operating terms).
The healthcare giant thus reported adjusted EPS of 2.95 dollars, with sales of 51.8 billion dollars, levels that are in line with its target ranges provided three months ago (from 2.94 dollars to three dollars and 51.2 billion to 52.2 billion dollars respectively).
For FY 2020, Pfizer expects adjusted EPS of between 2.82 dollars and 2.92 dollars, with sales of between 48.5 billion and 50.5 billion dollars (assuming the absence of share repurchases in 2020).
Copyright (c) 2020 CercleFinance.com. All rights reserved.
7 billion dollars (-8% in operating terms).
The healthcare giant thus reported adjusted EPS of 2.95 dollars, with sales of 51.8 billion dollars, levels that are in line with its target ranges provided three months ago (from 2.94 dollars to three dollars and 51.2 billion to 52.2 billion dollars respectively).
For FY 2020, Pfizer expects adjusted EPS of between 2.82 dollars and 2.92 dollars, with sales of between 48.5 billion and 50.5 billion dollars (assuming the absence of share repurchases in 2020).
Copyright (c) 2020 CercleFinance.com. All rights reserved.